GSK 4027 is a potent and selective inhibitor of the bromodomains of bromodomain and extra-terminal (BET) proteins, particularly BRD4. It is primarily utilized in research and development within the pharmaceutical industry for its potential therapeutic effects in oncology and inflammatory diseases. Researchers investigate its ability to modulate gene expression by targeting epigenetic regulators, studying efficacy and safety in preclinical models to assess suitability as a drug candidate. Applications focus on advancing understanding of disease mechanisms, such as cancer proliferation and immune responses, contributing to novel therapy discovery.